Search Results

You are looking at 1 - 10 of 164 items for :

Clear All
Full access

Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt, Sakshi Malhotra, Apar Kishor Ganti and Ketki K. Tendulkar

common immune-related adverse events are skin rash, diarrhea, and colitis. 1 , 3 , 4 Hypophysitis, although one of the most common endocrinopathies, is relatively uncommon with ipilimumab 1 , 3 , 4 and can be potentially difficult to diagnose. These

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz and Sharon Spencer

Institute of Canada Clinical Trials group . J Clin Oncol 2007 ; 25 : 1960 – 1966 . 16 Dudek AZ Kmak KL Koopmeiners J Keshtgarpour M . Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib

Full access

Mario E. Lacouture

contacts the dermatologist, who sees the patient within a day or 2 and then communicates the treatment plan to the oncologist.” Skin Rash Most FDA-approved targeted agents are associated with a wide spectrum of dermatologic toxicities.. Dr. Lacouture

Full access

Rachana Yendala, Kyaw Thein, Sriman Swarup, Anita Sultan, Somedeb Ball, Miguel Quirch, Myo H. Zaw, Yin M. Myat and Catherine Jones

Background: Pain, fatigue, hot flushes, and rash significantly contribute to quality of life in breast cancer patients undergoing chemotherapy. Hormone receptor-positive breast cancer is a common entity among women worldwide. In cancer cells, CDK4

Full access

Holly Dushkin and Massimo Cristofanilli

inflammatory breast cancer. The patient presented with skin rash and skin nodules. Diagnostic Modalities In most cases of IBC no discrete mass is palpable on clinical examination, but imaging studies may show an underlying mass and characteristic thickening of

Full access

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque and David G. Pfister

The median number of treatment cycles delivered was 2 for both groups (ranges, <1–13 for Group A; <1–15 for Group B). The most common cetuximab-related adverse events (all grades) among treated subjects included rash, fatigue, and hypomagnesemia

Full access

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla and Ghassan Bachuwa

-foot syndrome, 30%; hypertension, 27%; dysgeusia, 25%; hypothyroidism, 25%; cconstipation, 20%; stomatitis, 20%; inflammation of the mucosa, 18%; dyspepsia, 16%; vomiting, 14%; rash, 12%; asthenia, 11%; and epistaxis, 10%. Grade 3 (severe) AEs were reported in

Full access

Barbara Burtness

assortment of adverse skin effects are associated with the use of epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and erlotinib. Although papulopustular rash may be the most commonly observed side effect of these targeted agents, non-rash

Full access

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Lukman Tijani and Shabnam Rehman

any-grade mucocutaneous toxicities are as follows — palmar-plantar erythrodysesthesia (PPE): 0.83 (95% CI: 0.59-1.17, P = 0.29, I2 = 85%); rash: 1.28 (95% CI: 1.00-1.65, P = 0.05, I2 = 0%); pruritus: 2.68 (95% CI: 1.94-3.70, P < 0.00001, I2 = 0%); and

Full access

Komal Jhaveri and Francisco J. Esteva

reached and pertuzumab was well tolerated, with mostly grade 1 or 2 toxicities of asthenia (62%), vomiting (52%), nausea (48%), abdominal pain (48%), rash (43%), diarrhea (43%), and anemia (33%). One event of grade 3 dose-limiting toxicity (DLT